Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2025)

Vivos Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at $4.3 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $4.3 million for Q4 2025, up 41.94% from a year ago — trailing twelve months through Dec 2025 was $13.9 million (down 22.02% YoY), and the annual figure for FY2025 was $18.6 million, up 3.82%.
  • Cash from Financing Activities for Q4 2025 was $4.3 million at Vivos Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $25.4 million in Q2 2021 to a low of -$1.2 million in Q3 2021.
  • The 4-year median for Cash from Financing Activities is $3.6 million (2024), against an average of $5.5 million.
  • Peak annual rise in Cash from Financing Activities hit 1904.8% in 2021, while the deepest fall reached 164.4% in 2021.
  • Year by year, Cash from Financing Activities stood at -$1.2 million in 2021, then soared by 403.92% to $3.6 million in 2023, then dropped by 14.41% to $3.1 million in 2024, then surged by 41.94% to $4.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $4.3 million, $2.8 million, and $3.1 million for Q4 2025, Q3 2025, and Q4 2024 respectively.